The use of ABCG2 inhibitors and ABCB1 inhibitors, respectively, on ASPC-1 and H2170 cells with high ABCG2 expression and HCT15 cells with high ABCB1 expression can enhance the sensitivity of cancer cells to DXd/SN-38. This evidence concerns the gene ABCB1 and cancer.